Key facts
- Recludix Pharma’s last known valuation is $337.0M (Jan 2026).
- It has raised $123.0M; the latest was Later Stage VC ($21.5M) in Jan 2026.
- Notable investors include New Enterprise Associates, CONNECT (San Diego), Alexandria Venture Investments, Access Biotechnology, Eli Lilly — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Recludix Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Recludix Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Recludix Pharma
Operator of a drug discovery company intended to treat cancer and autoimmune diseases. The company's platform combines custom DNA-encoded libraries, massively parallel structure-activity relationship profiling, and proprietary selectivity screening tools, enabling pharmaceutical researchers and drug developers to address previously inaccessible protein targets, optimize candidate molecules through iterative design cycles, and advance novel therapies for inflammatory and immune-mediated conditions with improved precision and therapeutic potential.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 53
- Website
- recludixpharma.com/
- Ownership
- Privately Held (backing)
Recludix Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Recludix Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Recludix Pharma in its N-PORT filings yet. We sweep new filings monthly.